Key result
Oral valganciclovir successfully resolves fulminant cytomegalovirus myocarditis in a case report.
Why the study?
Cytomegalovirus myocarditis is uncommon in immunocompetent patients and its clinical course and treatment outcomes are not well characterized.
Case Report (n=1)
Oral valganciclovir may be an effective treatment for rare cases of fulminant cytomegalovirus myocarditis in immunocompetent patients.
Answers are grounded in this paper and cite their sources.
May support valganciclovir in rare fulminant CMV myocarditis; hypothesis-generating case report requiring prospective validation.
We report a case of fulminant myocarditis after a primary cytomegalovirus infection, in a previously healthy 72-year-old woman. The infection underwent clinical and immunologic resolution consequent to treatment with oral valganciclovir. In an immunocompetent host, the primary cytomegalovirus infection is usually asymptomatic or manifests itself as a heterophile-negative mononucleosis-like syndrome. Cytomegalovirus myocarditis is uncommon in immunocompetent patients. After presenting our case, we review the literature on cytomegalovirus myocarditis in immunocompetent individuals.
No takes yet. Share an insight, caveat, or question.
Padala et al. (2014) conducted a case report in Fulminant cytomegalovirus myocarditis (n=1). Oral valganciclovir was evaluated on Clinical and immunologic resolution. Treatment with oral valganciclovir led to clinical and immunologic resolution of fulminant cytomegalovirus myocarditis in a previously healthy 72-year-old woman.
Synapse has enriched 10 related papers. Consider them for comparative context: